Orchestra BioMed Holdings, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Orchestra BioMed Holdings, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $33.48M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $2.64M | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | $2.76M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $3.53M | Mar 27, 2024 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($52.70M) | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | ($61.02M) | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | ($49.12M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($33.61M) | Mar 27, 2024 |
| FY2022 | Dec 31, 2021 | ($378.8K) | Jan 25, 2023 |
| FY2020 | Dec 31, 2020 | ($173.5K) | Mar 31, 2022 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($51.81M) | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | ($64.30M) | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | ($51.51M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($32.66M) | Mar 27, 2024 |
| FY2022 | Dec 31, 2021 | ($394.8K) | Jan 25, 2023 |
| FY2021 | Dec 31, 2020 | ($180.0K) | Mar 31, 2022 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $58.19M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $42.80M | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | $33.82M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $21.95M | Mar 27, 2024 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $26.91M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $23.93M | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | $20.26M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $14.03M | Mar 27, 2024 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($48.96M) | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | ($50.56M) | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | ($46.13M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($29.29M) | Mar 27, 2024 |
| FY2022 | Dec 31, 2021 | ($272.4K) | Jan 25, 2023 |
| FY2020 | Dec 31, 2020 | ($258.5K) | Mar 31, 2022 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $489.0K | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $289.0K | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | $78.0K | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $591.0K | Mar 27, 2024 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $114.86M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $76.17M | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | $95.21M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $95.57M | Mar 27, 2024 |
| FY2022 | Dec 31, 2021 | $161.82M | Jan 25, 2023 |
| FY2021 | Dec 31, 2020 | $162.16M | Mar 31, 2022 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $51.48M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $43.22M | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | $27.17M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $43.04M | Mar 27, 2024 |
| FY2022 | Dec 31, 2021 | $5.77M | Jan 25, 2023 |
| FY2021 | Dec 31, 2020 | $5.72M | Mar 31, 2022 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | ($6.94M) | Jan 25, 2023 |
| FY2022 | Dec 31, 2021 | ($3.94M) | Jan 25, 2023 |
| FY2022 | Dec 31, 2020 | ($3.56M) | Jan 25, 2023 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($362.58M) | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | ($309.88M) | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | ($248.85M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($199.73M) | Mar 27, 2024 |
| FY2022 | Dec 31, 2021 | ($3.94M) | Jan 25, 2023 |
| FY2021 | Dec 31, 2020 | ($3.56M) | Mar 31, 2022 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $34.69M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $22.26M | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | $30.56M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $19.78M | Mar 27, 2024 |
| FY2022 | Dec 31, 2021 | $1.75M | Jan 25, 2023 |
| FY2021 | Dec 31, 2020 | $2.03M | Mar 31, 2022 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $15.00M | Mar 12, 2026 |
| FY2024 | Dec 31, 2024 | $15.00M | Mar 31, 2025 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | (1) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | (2) | Mar 27, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Jan 25, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | (1) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | (2) | Mar 27, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Jan 25, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 57.03M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | 38.19M | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | 35.78M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | 20.19M | Mar 27, 2024 |
| FY2022 | Dec 31, 2021 | 4.45M | Jan 25, 2023 |
| FY2021 | Dec 31, 2020 | 4.45M | Mar 31, 2022 |